Bolstered by the EU's blessing on its new hypertension treatment Rasilez, Novartis is planning a â‚¬183 million ($250 million) expansion of a plant near Basel, Switzerland. The expansion will boost production capacity of several high blood pressure meds, including top-seller Diovan and, of course, Rasilez.
Approved under the U.S. brand name Tekturna in March, Rasilez is a first-in-class treatment that targets renin, an enzyme that can trigger high blood pressure.
- check out the announcement on the approval
- and read this report
FDA approves Novartis' Tekturna. Report
Novartis files for FDA approval of Rasilez. Report
Novartis maps $100M R&D complex in China. Report
Novartis to build $600M flu plant in N.C. ReportÂ